Interviews

Please give us an overview of the REDUCE clinical study.

One of the challenges facing medicine today is how to best allocate resources. As medical costs continue to rise, agencies such as the Centers for Medicare & Medicaid Services (CMS) must ensure that money is spent in a responsible manner.

Gunnar Tepe, MD, Head of Diagnostic and Interventional Radiology at the Academic Hospital of Rosenheim, Rosenheim, Germany, described his experience with the Proteus device at the 2010 VEITHsymposium in New York.

Michel S. Makaroun, MD, Professor and Chief, Division of Vascular Surgery at the University of Pittsburgh Medical Center and primary scientific advisor for the Endurant Stent Graft IDE study, presented the study findings at the 2010...

You recently performed the first SFA implantation of the Misago™ stent as an investigator in the recently initiated OSPREY (Occlusive/ Stenotic Peripheral arteryREvascularization StudY) trial. What was your experience with this stent? What...

VDM speaks with Wesley S. Moore, MD, Professor and Chief Emeritus, Division of Vascular Surgery at UCLA Medical Center. At the 2010 VEITHsymposium, Dr. Moore discussed the need for a moratorium on both CEA and CAS to make way for a new trial...

At the recently concluded 37th Annual VEITHsymposium™ in New York, Peter H. Lin, MD, Professor of Surgery and Chief, Division of Vascular Surgery and Endovascular Therapy at Baylor College of Medicine (Houston, Texas), reported his findings...

Patients were included in the trial if they had lifestyle-limiting claudication (Rutherford categories 1–3) of at least 6 months’ duration and were candidates for angioplasty or stenting. They had to have de-novo or restenotic (not stented)...

What is the purpose and scope of the RESTORE- CLI trial? How many patients and centers will be involved in the Phase 3 trial, and when will it be completed?